ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti-PD-1 Therapy.
Ji Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.